Skip to content
value.today

Intercept Pharmaceuticals: financial analysis

Ratios worked out from 10 fiscal years of Intercept Pharmaceuticals's statements, compared with 665 companies in Biotechnology.

The newest statement on file is for fiscal 2022. The figures below describe that year, not Intercept Pharmaceuticals today.

Operating margin, 2022
-23.9%
Biotechnology: -60.5%
Revenue growth, 3 years a year, 2022
4.3%
Biotechnology: 12.9%
Debt to equity, 2022
2.40×
Biotechnology: 0.26×
Free cash flow margin, 2022
-9.6%
Biotechnology: -61.5%

Intercept Pharmaceuticals scorecard#

Passes 8 of the 15 checks that could be worked out: strongest in profitability (3 of 4), weakest in financial health (1 of 4). Fiscal year 2022.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 6
    • ✓Revenue grew in the newest year9.6%Revenue up 9.6% in fiscal 2022.
    • ✗Revenue up more than 5% a year over three years4.3%4.3% a year over the three years to fiscal 2022.
    • ✗Faster growth over three years than its peers' median4.3%4.3% a year against Biotechnology's median of 12.9% (181 companies).
    • ✓Earnings per share grew in the newest year6.56 vs -2.87Diluted EPS 6.56 in fiscal 2022 against -2.87 the year before (report's currency).
    • ✓Net income higher than five years earlier$222 M$222 M in fiscal 2022 against -$360 M in 2017.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2022.
  • Profitability3 of 4
    • ✓Profitable in the newest year$222 MNet income $222 M in fiscal 2022.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2022.
    • ✓Operating margin above its peers' median-23.9%-23.9% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-23.9%-23.9% in fiscal 2022 against -124.0% in 2019.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.35 at the end of fiscal 2022.
    • ✗Debt below equity2.4×Debt to equity 2.40 at the end of fiscal 2022.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-3.2×Operating income -3.2 times interest in fiscal 2022.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2022.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year6.1%Diluted shares up 6.1% in fiscal 2022.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2022 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Free cash flow was negative: -$27 million.
  • Only -12% of net income arrived as cash from operations.
  • The share count rose 6.1% in the year.
  • Operating income covers the interest bill only -3.2 times.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

5of 9
  • Made a profityes
  • Operations brought in cashno
  • Return on assets roseyes
  • Cash from operations exceeds profitno
  • Long-term debt fell against assetsyes
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin roseyes
  • Asset turnover roseyes

Profitability#

Intercept Pharmaceuticals: profitability by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Gross margin99.7%99.5%99.0%98.3%98.6%74.8%99%
Operating margin-23.9%-38.5%-98.2%-124.0%-158.8%-60.5%60%
Net margin77.6%-35.1%-117.5%-136.8%-172.0%-68.9%98%
Return on equity———-975.2%—-61.0%—
Return on assets41.1%-16.5%-41.2%-54.5%-62.3%-44.4%98%

Growth#

Intercept Pharmaceuticals: growth by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Revenue growth9.6%11.5%-7.2%40.2%37.3%15.8%43%
Revenue growth, 3 years a year4.3%13.2%21.3%116.2%301.4%12.9%38%
Revenue growth, 5 years a year16.9%59.9%142.7%170.5%—15.4%54%

Financial strength#

Intercept Pharmaceuticals: financial strength by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Debt to equity2.40×——10.32×19.41×0.26×7%
Net debt$173 M$455 M$502 M$462 M$328 M$-16 M8%
Interest cover-3.19×-1.85×-4.78×-7.59×-9.35×-22.77×82%
Current ratio2.35×3.02×3.05×4.45×4.22×4.39×27%
Equity share of assets16.8%-34.9%-28.7%6.8%3.8%64.7%22%

Cash#

Intercept Pharmaceuticals: cash by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Free cash flow$-27 M$-41 M$-176 M$-238 M$-241 M$-40 M58%
Free cash flow margin-9.6%-15.9%-75.1%-94.4%-134.0%-61.5%67%
Cash conversion-12.1%————72.6%26%
Capital spending share of revenue0.2%0.2%1.7%0.5%0.1%1.7%—

Shareholder returns#

Intercept Pharmaceuticals: shareholder returns by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Change in share count6.1%-3.3%4.2%——17.3%69%

Efficiency#

Intercept Pharmaceuticals: efficiency by fiscal year
Fiscal yearTrend20222021202020192018Median of peersAhead of
Asset turnover0.53×0.47×0.35×0.40×0.36×0.26×72%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).